Could venom-derived therapeutics resolve treatment resistance in refractory EAC?

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Esophageal adenocarcinoma (EAC) incidence is increasing globally, with poor prognosis and limited treatment options.
• Current chemotherapy and immunotherapy offer low 5-year survival rates (<15%) due to unpredictable treatment responses.
• Animal venoms are rich sources of diverse, potent bioactive peptides with therapeutic potential, though largely uncharacterized.

Purpose of the Study:

• To explore the therapeutic potential of venom-derived peptides for cancer treatment.
• To summarize the role of ion channels in the progression of esophageal adenocarcinoma.
• To discuss venom peptides targeting ion channels as a novel strategy for EAC therapy.

Main Methods:

• Literature review of venom-derived peptides and their anticancer properties.
• Review of current research on ion channel function in esophageal adenocarcinoma.
• Analysis of studies investigating venom peptides that modulate ion channels relevant to EAC.

Main Results:

• Animal venom peptides possess significant therapeutic potential due to their structural diversity and high potency.
• Ion channels play a critical role in the pathogenesis and progression of esophageal adenocarcinoma.
• Specific venom peptides targeting these ion channels have demonstrated promising preclinical activity.

Conclusions:

• Venom-derived peptides represent a promising, underexplored resource for novel cancer therapeutics.
• Targeting ion channels with specific venom peptides offers a potential new avenue for treating esophageal adenocarcinoma.
• Further research into pharmacologically characterizing venom peptides is crucial for developing new EAC treatments.